

Standard Biotools Inc. (LAB)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001162194

Standard Biotech Inc.

LAB; healthcare

Grade	D fourth fifth of 371 graded peers percentile 75.7; sampling error 2.5 points; lower is stronger
Rank	281 of 371
Profitability	D/E percentile 80.4
Solvency	C percentile 43.4
Growth and financing	C percentile 48.0
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$567.8M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	late filer; fortress balance sheet not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Mar 16, 2026 207 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$0.67 2026-10-08; market equity \$262.0M
Price used in grade	None

A photograph of a sloth hanging from a tree branch, surrounded by green leaves.

D, the sloth

fourth fifth of its sector; letters are fifths of the 371 graded peers


Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it

The chart shows the share price from November to September. The y-axis has labels at \$1 and \$3. The x-axis has labels for Nov, Jan, Mar, May, Jul, and Sep. The price starts around \$2.5 in Nov, peaks near \$3 in Dec, then declines steadily with some volatility, ending at \$0.67 in Sep. Rescan dates are marked with letters: B (Mar 21, 2023), E (Mar 21, 2024), and C (Mar 21, 2025). The current price point is labeled D.

Rescans on file: B from Mar 21, 2023, E from Mar 21, 2024, C from Mar 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 16, 2026

At Standard BioTools, Inc. ("Standard BioTools" or the "Company"), we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery,

translational and clinical research.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 80.4						
Gross profitability		7.5%	32.2%	79.8	372	2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(0.09%)	(6.6%)	81.1	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five consecutive annual gross margins are required
Solvency, sleeve percentile 43.4						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(1.44)	(0.31)	43.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		4.19x	2.96x	43.7	839	2025-12-31
Growth and financing, sleeve percentile 48.0						
Revenue growth, three-year compound		(4.5%)	10.0%	79.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		13.3%	2.1%	27.5	704	2025-12-31
Net share issuance, one year		2.9%	2.5%	37.4	634	2026-03-12


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Fortress balance sheet	cash minus debt is 166,429,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
276	Precision Optics Corporation, Inc. (POCI)	74.3	D	dilution, fortress balance sheet
277	Retractable Technologies Inc. (RVP)	74.6	D	fortress balance sheet
278	NutriBand Inc. (NTRB)	75.0	D	fortress balance sheet
279	NutriBand Inc. (NTRBW)	75.0	D	fortress balance sheet
280	Teleflex Inc. (TFX)	75.4	D	
281	Standard Biotech Inc. (LAB) <	75.7	D	late filer, fortress balance sheet
282	Abeona Therapeutics Inc. (ABEO)	75.9	D	fortress balance sheet
283	Cytosorbents Corp. (CTSO)	76.2	D	short runway, fortress balance sheet
284	Tilray Brands, Inc. (TLRY)	76.5	D	fortress balance sheet
285	Baxter International Inc. (BAX)	76.8	D	
286	Vivos Therapeutics, Inc. (VVOS)	77.0	D	dilution, short runway, late filer

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(49.3%)	8.0%	14
Distance from 52-week high	(60.1%)	(31.4%)	17
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(31.4%)	(1.0%)	17
Book value to price	2.05	0.28	97
Sales to price	0.32	0.31	53
Composite equity issuance, five years	166.1%	20.3%	86
Relative strength against the sector, log excess return	(0.89)	(0.14)	14

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$270.0M
Operating cash flow, four quarters	-\$80.3M
Months of runway	40.4
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$971,592

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$42.5M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
2	assets	us-gaap:Assets	\$567.8M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
3	operating income	us-gaap:OperatingIncomeLoss	-\$127.5M	2024-12-31	2026-03-16	10-K	0001193125-26-108326
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$90.4M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$542,000	2024-12-31	2026-03-16	10-K	0001193125-26-108326
6	total debt	us-gaap:LongTermDebt	\$299,000	2024-12-31	2025-03-11	10-K	0000950170-25-036608
7	book equity	us-gaap:StockholdersEquity	\$471.7M	2024-12-31	2026-03-16	10-K	0001193125-26-108326
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$166.7M	2024-12-31	2026-03-16	10-K	0001193125-26-108326
9	total debt	us-gaap:LongTermDebt	\$63.5M	2023-12-31	2025-03-11	10-K	0000950170-25-036608
10	book equity	us-gaap:StockholdersEquity	-\$148.1M	2023-12-31	2026-03-16	10-K	0001193125-26-108326
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$51.7M	2023-12-31	2025-03-11	10-K	0000950170-25-036608
12	net income	us-gaap:NetIncomeLoss	-\$74.9M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$74.3M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
14	assets	us-gaap:Assets	\$612.3M	2024-12-31	2026-03-16	10-K	0001193125-26-108326
15	current assets	us-gaap:AssetsCurrent	\$454.3M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
16	current liabilities	us-gaap:LiabilitiesCurrent	\$108.3M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.3B	2025-12-31	2026-03-16	10-K	0001193125-26-108326
18	operating income	us-gaap:OperatingIncomeLoss	-\$110.2M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
19	book equity	us-gaap:StockholdersEquity	\$424.3M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
20	liabilities	us-gaap:Liabilities	\$143.5M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
21	operating income	us-gaap:OperatingIncomeLoss	-\$76.6M	2023-12-31	2026-03-16	10-K	0001193125-26-108326
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$12.7M	2023-12-31	2024-03-01	10-K	0000950170-24-023845
23	interest expense	us-gaap:InterestExpense	\$4.6M	2023-12-31	2024-03-01	10-K	0000950170-24-023845
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$85.3M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$91.0M	2024-12-31	2026-03-16	10-K	0001193125-26-108326
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$106.3M	2023-12-31	2026-03-16	10-K	0001193125-26-108326
27	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$97.9M	2022-12-31	2025-03-11	10-K	0000950170-25-036608
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.3M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$143.5M	2024-12-31	2026-03-16	10-K	0001193125-26-108326
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.4M	2024-12-31	2026-03-16	10-K	0001193125-26-108326
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$43.3M	2023-12-31	2026-03-16	10-K	0001193125-26-108326
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.8M	2023-12-31	2026-03-16	10-K	0001193125-26-108326
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$89.4M	2022-12-31	2025-03-11	10-K	0000950170-25-036608
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.8M	2022-12-31	2025-03-11	10-K	0000950170-25-036608
35	depreciation amortization	us-gaap:Depreciation	\$6.9M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
36	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$96.7M	2025-12-31	2026-03-16	10-K	0001193125-26-108326

37	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$37.9M	2025-12-31	2026-03-16	10-K	0001193125-26-108326
38	current assets	us-gaap:AssetsCurrent	\$375.9M	2024-12-31	2026-03-16	10-K	0001193125-26-108326
39	current liabilities	us-gaap:LiabilitiesCurrent	\$65.9M	2024-12-31	2026-03-16	10-K	0001193125-26-108326
40	assets	us-gaap:Assets	\$323.1M	2023-12-31	2025-03-11	10-K	0000950170-25-036608
41	assets	us-gaap:Assets	\$390.3M	2022-12-31	2024-03-01	10-K	0000950170-24-023845
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	390,071,506	2026-03-12	2026-03-16	10-K	0001193125-26-108326
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	378,986,362	2025-03-02	2025-03-11	10-K	0000950170-25-036608